Markets:

Overview

News

Currencies

International

Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.040 -0.020 (-1.89%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023 ↗

April 13, 2023

Via Benzinga

Expert Ratings for Pliant Therapeutics ↗

April 13, 2023

Via Benzinga

Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference

April 12, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

The Latest Analyst Ratings for Pliant Therapeutics ↗

March 28, 2023

Via Benzinga

9 Analysts Have This to Say About Pliant Therapeutics ↗

March 10, 2023

Via Benzinga

Why Pliant Therapeutics Stock Is Skyrocketing This Week ↗

January 26, 2023

The company's experimental idiopathic pulmonary fibrosis drug is showing a lot of promise.

Via The Motley Fool

Expert Ratings for Pliant Therapeutics ↗

January 23, 2023

Via Benzinga

7 Biotech Stocks to Buy for 100% Returns ↗

April 09, 2023

If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio.

Via InvestorPlace

Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference

March 27, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis

March 13, 2023

Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue without modification and proceed to evaluate 320 mg dose

From Pliant Therapeutics, Inc.

Via GlobeNewswire

An Unexpected Feat Just Sent Pliant Therapeutics Soaring More Than 50% ↗

January 23, 2023

The company has a potentially best-in-class approach to a lung condition.

Via Investor's Business Daily

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results

March 09, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors

March 08, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Events

March 01, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Novartis Takes Down $80M NASH Pact With Pliant Therapeutics ↗

February 24, 2023

Via Benzinga

Pliant Therapeutics to Participate in Upcoming Investor Events

February 07, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

February 02, 2023

Phase 1 clinical study initiation expected in the second quarter of 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

January 27, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer

January 25, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Gaps 34% Higher: More Upside To Come?

January 25, 2023

Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.

Via MarketBeat

Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering

January 24, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces Proposed Public Offering of Common Stock

January 23, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Nasdaq Rises 1.5%; Pliant Therapeutics Shares Spike Higher ↗

January 23, 2023

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 150 points on Monday. The Dow traded up 0.46% to 33,527.51 while the NASDAQ rose 1.55% to 11,313.03. The...

Via Benzinga

Dow, Nasdaq Boasting Triple-Digit Midday Lead ↗

January 23, 2023

Investors seem intent on leaving last week's losses behind, as earnings season heats up.

Via Talk Markets

12 Health Care Stocks Moving In Monday's Intraday Session ↗

January 23, 2023

Via Benzinga

Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 23, 2023

Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 444.4% to $1.47 after the company announced it successfully completed the review of results from Milestone 7, a phase of its...

Via Benzinga

Dow Jumps Over 300 Points; Crude Oil Up 1% ↗

January 23, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 30 points on Monday. The Dow traded up 0.94% to 33,687.69 while the NASDAQ rose 1.93% to 11,355.16. The S&P 500...

Via Benzinga

Pliant Therapeutics (NASDAQ: PLRX) Reports Positive Phase 2 Clinical Trial Data of Bexotegrast in Treatment of Idiopathic Pulmonary Fibrosis

January 23, 2023

Pliant Therapeutics, Inc. (NASDAQ: PLRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development

Via Spotlight Growth

US Stocks Mostly Higher; Synchrony Financial Earnings Top Views ↗

January 23, 2023

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 90 points on Monday.

Via Benzinga

Why Is Xylem (XYL) Stock Down 9% Today ↗

January 23, 2023

Xylem (XYL) stock is slipping on Monday after the company revealed plans to acquire Evoqua (AQUA) in a $7.5 billion deal.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.